Dose-dependent pharmacokinetics of telithromycin after intravenous and oral administration to rats: Contribution of intestinal first-pass effect to low bioavailability

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 10, Issue 1, 2007, Pages 37-50

  Lee, Joo Hyun ^a   Lee, Myung Gull ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN SERUM ALBUMIN; TELITHROMYCIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; FIRST PASS EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; INJECTIONS, INTRAVENOUS; INTESTINES; KETOLIDES; KIDNEY; LIVER; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN;

EID: 34247628036     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Champney, W.S., and Tober, C.L., Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics. Curr Microbiol, 37:418-425, 1998.
2. Agouridas, C., Bonnefoy, A., Chantot, J.F., In vivo antibacterial activity of HMR3647, a novel ketolide highly active against respiratory pathogens, in Fourth International Conference on Macrolides, Azalides, Streptogramins and Ketolides. Barcelona, Spain, pp 21-23, 1998.
3. Roblin, P.M., and Hammerschlag, M.R., In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother, 42:1515-1516, 1998.
4. Perret, C., Lenfant, B., Weinling, E., Wessels, D.H., Scholtz, H.E., Montay, G., Sultan, E., Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers. Chemotherapy, 48:217-223, 2002.
5. Zhanel, G.G., Walters, M., Noreddin, A., Vercaigne, L.M., Wierzbowski, A., Embil, J.M., Gin, A.S., Douthwaite, S., Hoban, D.J., The ketolides: a critical review. Drugs, 62:1771-1804, 2002.
6. Thummel, K.E., Shen, D.D., Isoherranen, N., Smith, H.E., Appendices II. Design and optimization of dosage regimens: pharmacokinetic data, in Brunton, L.L., Lazo, J.S., Parker, K.L. (eds), Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed., McGraw-Hill, Medical Publishing Division, New York, NY, USA, p. 1876, 2006.
7. Namour, F., Wessels, D.H., Pascual, M.H., Reynolds, D., Sultan, E., Lenfant, B., Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother, 45:170-175, 2001.
8. Kim, S.H., Choi, Y.M., Lee, M.G., Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm, 21:1-17, 1993
9. Edelstein, P.H., and Edelstein, M.A., In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother, 43:90-95, 1999.
10. Murakami, T., Nakanishi, M., Yoshimori, T. Okamura, N., Norikura, R., Mizojiri, K., Separate assessment of intestinal and hepatic first-pass effects using a rat model with double cannulation of the portal and jugular veins. Drug Metab Pharmacokinet, 18:242-260, 2003.
11. Bae, S.K., Chung, W.-S., Kim, E.J., Rhee, J.K., Kwon, J.W., Kim, W.B., Lee, M.G., Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect. Antimicrob Agents Chemother, 48:659-662, 2004.
12. Yu, S.Y., Bae, S.K., Kim, E.J., Kim, Y.G., Kim, S.O., Lee, D.H., Lim, H., Lee, M.G. Dose-independent pharmacokinetics of a new reversible proton pump inhibitor, KR-60436, after intravenous and oral administration to rats: gastrointestinal first-pass effect. J Pharm Sci, 92:1592-1603, 2003
13. Lee, M.G., Chen, M.-L., Huang, S.-M., Chiou, W.L., Pharmacokinetics of drugs in blood. I. Unusual distribution of gentamicin. Biopharm Drug Dispos, 2:89-97, 1981.
14. Shim, H.J., Lee, E.J., Kim, S.H., Kim, S.H., You, M., Kwon, J.W., Kim, W.B., Lee, M.G., Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos, 21:285-291, 2000.
15. Chiou, W.L., Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm, 6:539-546, 1978.
16. Gibaldi, M., and Perrier, D., Pharmacokinetics. 2nd ed. Marcel-Dekker, New York, NY. USA, 1982.
17. Chiou, W.L., New calculation method of mean total body clearance of drugs and its application to dosage regimens. J Pharm Sci, 69:90-91, 1980.
18. Eatman, F.B., Colburn, W.A., Boxenbaum, H.G., Posmanter, H.N., Weinfeld, R.E., Ronfeld, R., Weissman, L., Moore, J.D., Gibaldi, M., Kaplan, S.A., Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm, 5:481-494, 1977.
19. Chiou, W.L., New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci, 68:1067-1069, 1979.
20. Chiou, W.L., Potential pitfalls in the conventional pharmacokinetic studies: effects of the initial mixing of drug in blood and the pulmonary first-pass elimination. J Pharmacokinet Biopharm, 7:527-536, 1979.
21. Lee, H.-J., and Chiou, W.L., Erythrocytes as barriers for drug elimination in the isolated rat liver I. Doxorubicin. Pharm Res, 6:833-839, 1989.
22. Lee, H.-J., and Chiou, W.L., Erythrocytes as barriers for drug elimination in the isolated rat liver. II. Propranolol. Pharm Res, 6:840-843, 1989.
23. Lee, J.H., and Lee, M.G., Effects of acute renal failure on the pharmacokinetics of telithromycin in rats: negligible effects of increase in CYP3A1 on the metabolism of telithromycin. Biopharm Drug Dispos, 2007 (in press).
24. Davies, B., and Morris, T., Physiological parameters in laboratory animals and humans. Pharm Res, 10:1093-1095, 1993.
25. Mitruka, B.M., and Rawnsley, H.M., Clinical Biomedical and Hematological Reference Values in Normal Experimental Animals and Normal Humans, 2nd ed. Masson Publishing USA, INC, New York, 1981.
26. Lee, M.G., and Chiou, W.L., Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm, 11:623-640, 1983.
27. Kaminsky, L.S., and Fasco, M.J., Small intestinal cytochromes P450. Crit Rev Toxicol, 21:407-422, 1991.